HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ortho-Clinical Diagnostics launches remote monitoring centre for Vitros systems

This article was originally published in Clinica

Ortho-Clinical Diagnostics has launched its Remote Monitoring Center (RMC) to continuously track the performance of its Vitros instruments. Vitros systems are used in clinical labs in a range of applications including the detection of drugs of abuse and diagnosis of infectious diseases. The RMC uses a secure, two-way broadband internet connection to detect and predict potential instrument problems before they interrupt a lab's ability to provide test results. The Raritan, New Jersey company hopes it will change instrument servicing from a "break-fix" to a "predict and maintain" model. The first centre is in Rochester, New York. The company is planning to open a second in Strasbourg, France, at the end of this year, and a third in the Asia-Pacific region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043904

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel